Cargando…

A pilot study of quality of life, mood, sleepiness and fatigue in patients with primary humoral immunodeficiency transitioning to subcutaneous immunoglobulin therapy

Detalles Bibliográficos
Autores principales:	Pourshahnazari, Persia, Tsai, Gina, Martin, Adriana, Kanani, Amin, Stark, Donald, Schellenberg, R Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304089/ http://dx.doi.org/10.1186/1710-1492-10-S2-A37

Ejemplares similares

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
por: Martin, Adriana, et al.
Publicado: (2012)

Buckwheat anaphylaxis: a case report
por: Pourshahnazari, Persia, et al.
Publicado: (2014)

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
por: Keith, Paul K., et al.
Publicado: (2022)

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
por: Keith, Paul K., et al.
Publicado: (2023)

The role of C1 inhibitor and complement as acute phase reactants: are we missing the diagnosis of hereditary angioedema?
por: Stepaniuk, Peter, et al.
Publicado: (2021)

Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
por: Martin, Adriana, et al.
Publicado: (2012)

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency
por: Ducruet, Thierry, et al.
Publicado: (2011)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Oral allergy syndrome and risk of food-related anaphylaxis: a cross-sectional survey analysis
por: Jagdis, Amanda, et al.
Publicado: (2011)

A Prospective Clinical Trial of Prolonged Fasting in Healthy Young Males and Females—Effect on Fatigue, Sleepiness, Mood and Body Composition
por: Nugraha, Boya, et al.
Publicado: (2020)

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
por: Borte, Michael, et al.
Publicado: (2023)

Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy
por: Gernez, Yael, et al.
Publicado: (2018)

Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura
por: Chapdelaine, H, et al.
Publicado: (2012)

Improved quality of life with home therapy with subcutaneous immunoglobulins for patients with secondary hypogammaglobulinaemia
por: Levasseur, Marie-Claude, et al.
Publicado: (2012)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients
por: Schroeder, H. W., et al.
Publicado: (2012)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia
por: Mustafa, S. Shahzad, et al.
Publicado: (2021)

Relationships Between Sleepiness, Mood, and Neurocognitive Performance in Military Personnel
por: Haran, F. J., et al.
Publicado: (2019)

O004 The effect of treating OSA with CPAP on mood and sleepiness
por: Tolson, J, et al.
Publicado: (2023)

Céphalées en coup de tonnerre récurrentes dues à un syndrome de vasoconstriction cérébrale réversible associé à la duloxétine, à la xylométazoline et à une rhinite médicamenteuse
por: Pham, Hoang, et al.
Publicado: (2021)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
por: Kobrynski, Lisa
Publicado: (2012)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience
por: Thalappil, Sherin, et al.
Publicado: (2023)

Quantitative indicators of street lighting with mood, fatigue, mental workload and sleepiness in car drivers: Using generalized structural equation modeling
por: Madvari, Rohollah Fallah, et al.
Publicado: (2023)

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
por: Li, Zhaoyang, et al.
Publicado: (2023)

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies
por: Shabaninejad, Hosein, et al.
Publicado: (2017)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
por: Mallick, R., et al.
Publicado: (2020)

Safety, efficiency, and treatment satisfaction in children with primary immunodeficiency receiving subcutaneous immunoglobulin treatment
por: Eltan, Sevgi Bilgic, et al.
Publicado: (2022)

Daytime Sleepiness in Parkinson's Disease: Perception, Influence of Drugs, and Mood Disorder
por: Ataide, M., et al.
Publicado: (2014)

Ecological momentary assessment of fatigue, sleepiness, and exhaustion in ESKD
por: Abdel-Kader, Khaled, et al.
Publicado: (2014)

Cancer-related fatigue presenting with excessive daytime sleepiness
por: Balachandran, Diwakar D, et al.
Publicado: (2017)

Sleep, Sleepiness, and Fatigue on Board Faroese Fishing Vessels
por: Abrahamsen, Annbjørg, et al.
Publicado: (2022)

Unusual presentation of a patient with complement deficiency and immunoglobulin deficiency
por: Manga, Vaishaali, et al.
Publicado: (2014)

Basic and clinical immunology – 3030. Subcutaneous immunoglobulin therapy: An option for patients who have experienced thrombotic complications with intravenous therapy
por: Moss, Leslie Anne, et al.
Publicado: (2013)

Cutaquig(®) Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products
por: Brownlee, Sydney, et al.
Publicado: (2022)

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases
por: Fasshauer, Maria, et al.
Publicado: (2023)

Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
por: Kanegane, Hirokazu, et al.
Publicado: (2014)

Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
por: Walter, Graham, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ck0hebps4al9du5s00ausl2203